关键词: 乳腺肿瘤, 芳香化酶抑制剂, 骨关节症状, 证据总结, 循证护理学

Abstract:

Objective To retrieve，evaluate and summarize domestic and foreign latest evidence on the prevention and management in breast cancer patients for aromatase inhibitors-induced musculoskeletal symptoms. Methods We systematically searched relevant guideline networks and association websites，as well as Cochrane Library，JBI，PubMed，Web of Science Core Collection，Embase，CINAH，CNKI，VIP，Wanfang，and CBM to collect guidelines，expert consensuses，systematic reviews，and meta-analyses，best practices and recommended practices related to preventions and management about breast cancer patients for aromatase inhibitors-induced musculoskeletal symptoms. The retrieval period was from the inception of databases to July 12，2022. There were 2 researchers who independently evaluated the quality of included literature，and extracted and summarized the evidence. Results A total of 21 articles were incorporated，including 1 guideline，3 expert consensuses，and 17 systematic reviews or meta-analyses. Finally，37 pieces of best evidence including 8 aspects were summarized，namely incidence，clinical features，symptom assessment，risk assessment，prevention，pharmacotherapy，non-pharmacotherapy，and management strategy. There were 17 pieces of Level-1 evidence. Conclusion The best evidence for prevention and management in breast cancer patients for aromatase inhibitors-induced musculoskeletal symptoms could provide references to develop the plan of symptom management and conduct the best clinical practice of clinicians and nurses，but the best evidence should be selected according to the clinical situations and patients’ preferences.

Key words: Breast Neoplasms, Aromatase Inhibitors, Musculoskeletal Symptoms, Evidence Summary, Evidence-Based Nursing